IRadimed Corporation
NASDAQ:IRMDMedical - Devices
+$0.67 today
- Market cap
- $1.05B
- Beta
- 0.92
- P/E (TTM)
- 49.7
- EPS (TTM)
- $1.85
- Dividend yield
- 1.35%
Volume 0.08M
Average 0.12M
IRMD Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
IRadimed CorporationNASDAQ: IRMD
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables rises 5.6% from a year ago
Net receivables stood at $13.42M at the end of Q1 FY2026, up 5.6% from a year earlier and down 1.8% from the prior quarter. Over 3 fiscal years it compounded at +1.0% a year.
Context
- Net receivables amounted to 11.7% of total assets at the end of Q1 FY2026, down 0.8 pp from a year earlier.
- Net receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +5.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 13.67M USD
- Year-over-year change
- +29.5%
- 4-year CAGR
- +27.7%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.67M | +29.5% |
| FY2024 | 2024-12-31 | 10.56M | -13.6% |
| FY2023 | 2023-12-31 | 12.22M | -7.9% |
| FY2022 | 2022-12-31 | 13.27M | +158.4% |
| FY2021 | 2021-12-31 | 5.14M | — |
Net Receivables vs competitors
How IRMD compares with its peers on the latest reported figures
- IRMD's Mar 2026 net receivables of $13.42M is the lowest of the 11 companies compared; the peer median is $124.15M.
- Its year-over-year change of +5.6% is the 6th highest of 11, against a peer median of +7.6%.
- Net receivables amounts to 11.7% of total assets for IRMD, versus a peer median of 6.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Apr 2026 | $391.97M | -6.3% | +1.1% | 8.9% | |
| Mar 2026 | $264.41M | +4.7% | +1.9% | 7.4% | |
| Mar 2026 | $244.62M | +42.2% | +28.0% | 12.1% | |
CTEVClaritev Corporation | Mar 2026 | $154.22M | +32.3% | +20.5% | 3.2% |
| Mar 2026 | $140.67M | +11.1% | +13.0% | 12.2% | |
| Mar 2026 | $107.62M | -16.4% | -5.3% | 5.8% | |
| Mar 2026 | $52.54M | +65.5% | +22.3% | 4.5% | |
| Mar 2026 | $46.03M | -26.1% | +20.7% | 14.9% | |
| Mar 2026 | $40.7M | -29.7% | +20.4% | 5.4% | |
| Sep 2026 | $34.01M | +10.5% | +5.7% | 6.2% | |
| Mar 2026 | $13.42M | +5.6% | +1.0% | 11.7% | |
| Peer median (excluding IRMD) | $124.15M | +7.6% | +16.7% | 6.8% | |
Competitors are the stored peer set for IRMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 62M | 57.96M | 49.76M | 52.23M | 51.16M |
| Short-term Investments | 501.86K | 0 | 0 | 0 | 0 |
| Net Receivables | 5.14M | 13.27M | 12.22M | 10.56M | 13.67M |
| Inventory | 4.3M | 5.37M | 12.82M | 10.4M | 11.62M |
| Other Current Assets | 1M | 630.96K | 1.19M | 2.05M | 4.76M |
| Total Current Assets | 76.24M | 77.49M | 76M | 75.24M | 81.2M |
| Property, Plant & Equipment (Net) | 4.55M | 4.61M | 11.33M | 16.97M | 23.86M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 1.12M | 2.07M | 2.52M | 3.1M | 3.38M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 765.1K | 700.87K | 2.12M | 2.82M | 94K |
| Other Non-current Assets | 201.33K | 648.67K | 181.45K | 198.91K | 239K |
| Total Non-current Assets | 6.64M | 8.02M | 16.15M | 23.08M | 27.57M |
| Total Assets | 82.88M | 85.51M | 92.16M | 98.33M | 108.78M |
| Account Payables | 782.9K | 1.8M | 1.86M | 1.9M | 1.82M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 140.32K | 121.92K | 353.28K | 163K | 0 |
| Deferred Revenue | 2.55M | 3.37M | 2.57M | 2.26M | 2.87M |
| Other Current Liabilities | 255.32K | 94.03K | 367.46K | 268.27K | 457K |
| Total Current Liabilities | 6.82M | 8.55M | 16.33M | 8.51M | 10.18M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 1.68M | 1.38M | 2.79M | 2.99M | 3.98M |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 3.88M | 3.29M | 4.41M | 2.99M | 3.98M |
| Total Liabilities | 10.71M | 11.84M | 20.74M | 11.51M | 14.16M |
| Common Stock | 1.25K | 1.26K | 1.27K | 1.27K | 1K |
| Retained Earnings | 46.99M | 47.26M | 43.26M | 56.79M | 64.23M |
| Accumulated OCI | 17.01K | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 72.17M | 73.67M | 71.42M | 86.82M | 94.62M |
| Total Debt | 2.48M | 2.21M | 2.04M | 154.69K | 0 |
| Net Debt | (59.52M) | (55.76M) | (47.72M) | (52.08M) | (51.16M) |
IRadimed Corporation
NASDAQ:IRMD
Intrinsic Alpha fair value
Locked
Current Price
$82.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.